POPPY II Cohort Profile– a population-based linked cohort examining the patterns and outcomes of prescription opioid use in NSW, Australia, 2003-2018.
Objectives Although opioid prescribing and harms have increased in Australia, there is a lack of population-level evidence about the drivers of long-term opioid use, dependence and other harms. This study aims to profile the POPPY II cohort, with respect to sociodemographic and clinical health chara...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Swansea University
2022-08-01
|
| Series: | International Journal of Population Data Science |
| Subjects: | |
| Online Access: | https://ijpds.org/article/view/1966 |
| _version_ | 1797430591287721984 |
|---|---|
| author | Natasa Gisev Sallie-Anne Pearson Timothy Dobbins Luke Buizen Tom Murphy Andrew Wilson Fiona Blyth Adrian Dunlop Sarah Larney David C. Currow Richard P. Mattick Louisa Degenhardt |
| author_facet | Natasa Gisev Sallie-Anne Pearson Timothy Dobbins Luke Buizen Tom Murphy Andrew Wilson Fiona Blyth Adrian Dunlop Sarah Larney David C. Currow Richard P. Mattick Louisa Degenhardt |
| author_sort | Natasa Gisev |
| collection | DOAJ |
| description | Objectives
Although opioid prescribing and harms have increased in Australia, there is a lack of population-level evidence about the drivers of long-term opioid use, dependence and other harms. This study aims to profile the POPPY II cohort, with respect to sociodemographic and clinical health characteristics and patterns of opioid initiation.
Approach
The POPPY II cohort includes adult residents (≥18 years) in NSW who were initiated on prescribed opioids subsidised through Australia’s Pharmaceutical Benefits Scheme for any period between 1st July 2003 and 31st December 2018. The cohort has been linked to nine other datasets containing information on socio-demographic and clinical characteristics, health service use, and adverse outcomes.
Results
There were 3,569,433 people in the cohort. One in four people were aged ≥65 years at the time of opioid initiation (26.8%) and half were female (52.7%). About 71% resided in a major city. Approximately 6% had evidence of being treated for cancer in the year prior to opioid initiation (5.8%). In the 3 months prior to cohort entry, 27% used an analgesic medicine and 21% used a psychotropic medicine. Less than a third initiated on a strong opioid (22.2%) and the most commonly initiated opioid was paracetamol/codeine (61.3%).
Conclusion
The POPPY II study is the largest post-marketing surveillance study of prescribed opioids in Australia, and one of the largest studies worldwide. Understanding the characteristics of the cohort will inform future work aimed at generating robust evidence of the long-terms patterns and outcomes of prescribed opioid use in the Australian community.
|
| first_indexed | 2024-03-09T09:30:46Z |
| format | Article |
| id | doaj.art-394262b1941e4bd9bb2b2b4ddde7bd69 |
| institution | Directory Open Access Journal |
| issn | 2399-4908 |
| language | English |
| last_indexed | 2024-03-09T09:30:46Z |
| publishDate | 2022-08-01 |
| publisher | Swansea University |
| record_format | Article |
| series | International Journal of Population Data Science |
| spelling | doaj.art-394262b1941e4bd9bb2b2b4ddde7bd692023-12-02T03:57:44ZengSwansea UniversityInternational Journal of Population Data Science2399-49082022-08-017310.23889/ijpds.v7i3.1966POPPY II Cohort Profile– a population-based linked cohort examining the patterns and outcomes of prescription opioid use in NSW, Australia, 2003-2018.Natasa Gisev0Sallie-Anne Pearson1Timothy Dobbins2Luke Buizen3Tom Murphy4Andrew Wilson5Fiona Blyth6Adrian Dunlop7Sarah Larney8David C. Currow9Richard P. Mattick10Louisa Degenhardt11National Drug and Alcohol Research Centre, UNSW SydneyCentre for Big Data Research in Health, UNSW Sydney, Sydney AustraliaSchool of Population Health, Faculty of Medicine and Health, UNSW Sydney, Sydney AustraliaNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney AustraliaNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney AustraliaMenzies Centre for Health Policy, Faculty of Medicine and Health, The University of Sydney, Sydney, AustraliaSchool of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, AustraliaSchool of Medicine and Public Health, Faculty of Health, The University of Newcastle, Newcastle AustraliaCentre de Recherche du Centre Hospitalier de l'Université de Montréal, Université de MontréalFaculty of Science, Medicine and Health, University of Wollongong, Wollongong. New South Wales AustraliaNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney AustraliaNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney AustraliaObjectives Although opioid prescribing and harms have increased in Australia, there is a lack of population-level evidence about the drivers of long-term opioid use, dependence and other harms. This study aims to profile the POPPY II cohort, with respect to sociodemographic and clinical health characteristics and patterns of opioid initiation. Approach The POPPY II cohort includes adult residents (≥18 years) in NSW who were initiated on prescribed opioids subsidised through Australia’s Pharmaceutical Benefits Scheme for any period between 1st July 2003 and 31st December 2018. The cohort has been linked to nine other datasets containing information on socio-demographic and clinical characteristics, health service use, and adverse outcomes. Results There were 3,569,433 people in the cohort. One in four people were aged ≥65 years at the time of opioid initiation (26.8%) and half were female (52.7%). About 71% resided in a major city. Approximately 6% had evidence of being treated for cancer in the year prior to opioid initiation (5.8%). In the 3 months prior to cohort entry, 27% used an analgesic medicine and 21% used a psychotropic medicine. Less than a third initiated on a strong opioid (22.2%) and the most commonly initiated opioid was paracetamol/codeine (61.3%). Conclusion The POPPY II study is the largest post-marketing surveillance study of prescribed opioids in Australia, and one of the largest studies worldwide. Understanding the characteristics of the cohort will inform future work aimed at generating robust evidence of the long-terms patterns and outcomes of prescribed opioid use in the Australian community. https://ijpds.org/article/view/1966analgesicsdrug utilizationopioidspainpharmacoepidemiology |
| spellingShingle | Natasa Gisev Sallie-Anne Pearson Timothy Dobbins Luke Buizen Tom Murphy Andrew Wilson Fiona Blyth Adrian Dunlop Sarah Larney David C. Currow Richard P. Mattick Louisa Degenhardt POPPY II Cohort Profile– a population-based linked cohort examining the patterns and outcomes of prescription opioid use in NSW, Australia, 2003-2018. International Journal of Population Data Science analgesics drug utilization opioids pain pharmacoepidemiology |
| title | POPPY II Cohort Profile– a population-based linked cohort examining the patterns and outcomes of prescription opioid use in NSW, Australia, 2003-2018. |
| title_full | POPPY II Cohort Profile– a population-based linked cohort examining the patterns and outcomes of prescription opioid use in NSW, Australia, 2003-2018. |
| title_fullStr | POPPY II Cohort Profile– a population-based linked cohort examining the patterns and outcomes of prescription opioid use in NSW, Australia, 2003-2018. |
| title_full_unstemmed | POPPY II Cohort Profile– a population-based linked cohort examining the patterns and outcomes of prescription opioid use in NSW, Australia, 2003-2018. |
| title_short | POPPY II Cohort Profile– a population-based linked cohort examining the patterns and outcomes of prescription opioid use in NSW, Australia, 2003-2018. |
| title_sort | poppy ii cohort profile a population based linked cohort examining the patterns and outcomes of prescription opioid use in nsw australia 2003 2018 |
| topic | analgesics drug utilization opioids pain pharmacoepidemiology |
| url | https://ijpds.org/article/view/1966 |
| work_keys_str_mv | AT natasagisev poppyiicohortprofileapopulationbasedlinkedcohortexaminingthepatternsandoutcomesofprescriptionopioiduseinnswaustralia20032018 AT sallieannepearson poppyiicohortprofileapopulationbasedlinkedcohortexaminingthepatternsandoutcomesofprescriptionopioiduseinnswaustralia20032018 AT timothydobbins poppyiicohortprofileapopulationbasedlinkedcohortexaminingthepatternsandoutcomesofprescriptionopioiduseinnswaustralia20032018 AT lukebuizen poppyiicohortprofileapopulationbasedlinkedcohortexaminingthepatternsandoutcomesofprescriptionopioiduseinnswaustralia20032018 AT tommurphy poppyiicohortprofileapopulationbasedlinkedcohortexaminingthepatternsandoutcomesofprescriptionopioiduseinnswaustralia20032018 AT andrewwilson poppyiicohortprofileapopulationbasedlinkedcohortexaminingthepatternsandoutcomesofprescriptionopioiduseinnswaustralia20032018 AT fionablyth poppyiicohortprofileapopulationbasedlinkedcohortexaminingthepatternsandoutcomesofprescriptionopioiduseinnswaustralia20032018 AT adriandunlop poppyiicohortprofileapopulationbasedlinkedcohortexaminingthepatternsandoutcomesofprescriptionopioiduseinnswaustralia20032018 AT sarahlarney poppyiicohortprofileapopulationbasedlinkedcohortexaminingthepatternsandoutcomesofprescriptionopioiduseinnswaustralia20032018 AT davidccurrow poppyiicohortprofileapopulationbasedlinkedcohortexaminingthepatternsandoutcomesofprescriptionopioiduseinnswaustralia20032018 AT richardpmattick poppyiicohortprofileapopulationbasedlinkedcohortexaminingthepatternsandoutcomesofprescriptionopioiduseinnswaustralia20032018 AT louisadegenhardt poppyiicohortprofileapopulationbasedlinkedcohortexaminingthepatternsandoutcomesofprescriptionopioiduseinnswaustralia20032018 |